Royalty Pharma PLC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Royalty Pharma plc files an amendment to its Schedule 13D, updating beneficial ownership details for Pablo Legorreta and Legorreta Investments, LLC, reflecting changes in outstanding shares.
NASDAQ
SCHEDULE: Royalty Pharma: Stakeholder Exits Filing
Butterfield Fiduciary Administrators Trust Company Limited and Achille G. Severgnini have filed an exit report for their beneficial ownership of Royalty Pharma plc Class A Ordinary Shares, indicating a reduction in their stake to below 5%.
NASDAQ
SCHEDULE 13D: Royalty Pharma CEO Pablo Legorreta Significantly Increases Beneficial Ownership to Nearly 20% Following Strategic Transaction
Royalty Pharma plc's CEO and Chairman, Pablo Legorreta, along with Legorreta Investments, LLC, have disclosed a substantial increase in their beneficial ownership of the company's Class A ordinary shares, reaching 19.74% and 8.14% respectively, primarily due to a strategic acquisition transaction.
NASDAQ
SCHEDULE 13D/A: Major Shareholders Reduce Stake in Royalty Pharma plc, Selling Over 4.9 Million Shares
Key shareholders, GG Strategic and MGG Strategic, have significantly reduced their holdings in Royalty Pharma plc, selling over 4.9 million Class A Ordinary Shares in recent open market transactions.
NASDAQ
R & H Trust Co. (Guernsey) Limited and Achille G. Severgnini have filed an amended Schedule 13D for Royalty Pharma plc, revealing a beneficial ownership of 8.3% and significant share sales in the past 60 days.